Spectral AI (MDAI) announced that the final group of burn center patients in the Company’s U.S. Burn Pivotal Study have successfully completed their clinical visits. “The completion of this aspect of the U.S. Burn Pivotal Study marks a critical milestone on our path towards commercialization,” said Dr. J. Michael DiMaio, Chairman of the Board. “These results will form the foundation of our forthcoming U.S. regulatory submission and brings us one step closer to delivering a potentially groundbreaking advancement in burn wound assessment that can support clinical decision-making regarding next step treatment plans, broaden equity in access to burn care treatment, and improve clinical outcomes. I want to thank our investigators, their dedicated staff, and study enrollees for their support in this endeavor.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDAI:
- Spectral AI files $50M common stock offering
- Spectral AI’s Leadership Change and Strategic Shift
- Spectral AI appoints DiMaio as Chairman of the Board of Directors
- Spectral AI completes proof of concept for wound measurement technology
- Spectral AI achieves 25% patient enrollment at ED for Burn Pivotal Study